Mucosal mucin secretion and respiratory epithelial mucosa

Mucosal mucin secretion and the respiratory epithelial mucosa represent a complex physiological system rather than a single molecular target. This system is responsible for the production and clearance of mucus, which serves as a primary innate immune defense by trapping and removing inhaled pathogens and particulates (Source: Fahy & Dickey, N Engl J Med, 2010). The mucosa consists of a specialized epithelium containing goblet cells and submucosal glands that secrete high-molecular-weight glycoproteins known as mucins, primarily MUC5AC and MUC5B (Source: Ma et al., Postgrad Med J, 2015). In healthy states, the mucus is efficiently cleared by the coordinated beating of ciliated cells in a process termed mucociliary clearance. In chronic respiratory diseases such as asthma, COPD, and cystic fibrosis, this system becomes dysfunctional, characterized by mucin hypersecretion, altered viscoelastic properties, and impaired clearance, leading to airway obstruction and chronic inflammation (Source: Rogers, Respirology, 2003). Pharmacological strategies do not target the mucosa as a whole but rather specific components, such as the chemical structure of mucins (mucolytics), the neural control of secretion (anticholinergics), or the hydration of the airway surface (osmotic agents). Because this entry describes a broad physiological process and anatomical structure rather than a specific protein or receptor, it is classified as an incorrect target designation for structured drug discovery databases.

Other names

Airway mucus secretionRespiratory mucociliary systemBronchial mucus productionAirway surface liquid (ASL) homeostasis

Drugs interacting with this system function through several mechanisms: mucolytics like N-acetylcysteine reduce mucus viscosity by hydrolyzing disulfide bonds between mucin monomers (Source: PubChem, CID 12035); anticholinergics like Ipratropium inhibit M3 muscarinic receptors on submucosal glands to decrease secretion volume (Source: StatPearls, Ipratropium); and beta-2 agonists enhance mucociliary clearance by increasing ciliary beat frequency (Source: Fahy & Dickey, N Engl J Med, 2010).